Buformin

This classification denotes an anti-diabetic agent with the molecular formula C6H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W2115E9C7B, chemically known as imidodicarbonimidic diamide, n-butyl- but more generally known as buformin, which bears US NIH Compound Identifier 2468. Buformin most often comes in base and hydrochloride forms. European Medicines Agency schedules Buformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05965MIG. The term BUFORMIN is an International Non-Proprietary Name WHO schedules buformin in its Anatomical Therapeutic Chemical (ATC) Classification. BUFORMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule buformin under HS 29252900 and SITC 51482. As of Q4 2014, BUFORMIN remains US FDA's Preferred Term for this commodity. Buformin bears US NLM identifiers UMLS ID C0006359 and NCI Concept Code C95328. SMILES: N(=C(\N=C(\N)N)N)/CCCC.